Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT05114785

Heart Failure With Preserved Ejection Fraction: Evaluation and Recognition by CMR

Heart failure with preserved ejection fraction (HFpEF) is a common and growing condition with a poor prognosis but the pathophysiology and management are still being investigated. The PREFER-CMR project aims to evaluate and validate the application of novel 4D cardiac magnetic resonance flow dynamic methods to measure left ventricular pressures and validate these measurements with direct pressure measurement by coronary angiography. This is a prospective observational study of patients with HFpEF undergoing clinical evaluation with coronary angiography who will also undergo contemporaneous cardiac MRI. The primary outcome will be the level of agreement between the two methods using angiography as the reference method.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

Heart failure with preserved ejection fraction (HFpEF) is prevalent, increasing in incidence and has a poor prognosis. Accurate left ventricular (LV) haemodynamic assessment is needed to diagnose and manage patients with HFpEF. The reference method for assessment is an invasive study using catheters to measure intra-ventricular pressure but this is rarely done due to its invasive nature, high procedural costs and lack of expertise, despite the fact that haemodynamic guided therapy is associated with reduced re-hospitalisation and mortality. Non-invasive methods of LV haemodynamic assessment are inaccurate. The Investigators have developed an accurate four-dimensional flow cardiac magnetic resonance (4D flow CMR) protocol which is non-invasive and addresses the issues with existing practices to evaluate HFpEF. This observational-analytical study aims to assess the utility of a non-invasive 4D flow CMR protocol for haemodynamic assessment of HFpEF, to generate clinical data to support future clinical trials, clinical translation and patient benefit. This research study will involve generating a precise haemodynamic model using invasive and non-invasive data of prospectively recruited patients. This model will be also optimised in clinical patients with arrhythmias. Also, observational data will be collected to test the model's prognostic value.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults: age≥18 years.
  • Typical HF symptoms (NYHA stage>I) within the last six months.
  • Raised NTproBNP (>400 pg/ml)
  • EF>50 % with the absence of structural heart disease on TTE (except left ventricular hypertrophy or left atrial enlargement).

Exclusion criteria

  • Patients unable/unwilling to provide informed consent.
  • Bodyweight>120 kg or inability to lie flat/still.
  • Contraindication for invasive workup (allergy to contrast, severe renal insufficiency with estimated glomerular filtration rate (eGRF)<30 ml/min).
  • Contraindications for a contrast-enhanced CMR study (allergy to contrast, incompatible devices or implants, severe claustrophobia).
  • Previous medical history of EF <50%
  • Pregnancy

The extended observational arm of the study will have wider eligibility criteria

  • Patients undergoing cardiac MRI for clinical indications irrespective of EF

Treatment and study plan

Multi Parametric Cardiac Magnetic Resonance

Diagnostic Test

Research based Cardiac MRI evaluation to determine cardiovascular haemodynamics

Primary outcomes

  1. Left ventricular pressure measured by invasive angiography (reference method) and modelled by cardiovascular magnetic resonance imaging

    Time frame: 30 days

    Agreement of invasively measured left ventricular pressure in millimeters of mercury (mmHg) by invasive angiography to non-invasively modelled left ventricular pressure by cardiac magnetic resonance imaging. The agreement will be tested by Bland-Altman plots..

Secondary outcomes

  1. Prognostic relevance of left ventricular pressures measured by cardiac MRI

    Time frame: Ten years

    Is cardiovascular magnetic resonance modelled left ventricular pressure in millimeters of mercury (mmHg) associated with MACE events including re-hospitalization, stroke, myocardial infarction and death. Association between pressure measurements and MACE will be tested by Cox proportional hazards regression and Kaplan-Meier survival analysis.

Study contacts

Contact information is provided by the study sponsor or research team.

Marcus D Flather, MBBS

CONTACT

[email protected]

Pankaj Garg, MD

CONTACT

[email protected]

+441603591721

Sponsors and collaborators

Lead sponsor

University of East Anglia

Other

Collaborators

  • Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK)

Registry information

Official study title

PReserved Ejection Fraction Evaluation and Recognition by Cardiac Magnetic Resonance

Acronym: PREFER-CMR

Important dates

Study start
2022
Primary completion
2026
Study completion
2032
First posted
Nov 10, 2021
Registry last updated
Jan 5, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.